Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.

PubWeight™: 1.41^‹?› | Rank: Top 5%

🔗 View Article (PMID 26839066)

Published in Heart on February 02, 2016

Authors

Ziad Hijazi¹, Julia Aulin¹, Ulrika Andersson², John H Alexander³, Bernard Gersh⁴, Christopher B Granger³, Michael Hanna⁵, John Horowitz⁶, Elaine M Hylek⁷, Renato D Lopes³, Agneta Siegbahn⁸, Lars Wallentin¹, ARISTOTLE Investigators

Author Affiliations

1: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
2: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
3: Duke University Medical Center, Durham, North Carolina, USA.
4: Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
5: Bristol-Myers Squibb, Princeton, New Jersey, USA.
6: Cardiology Department, University of Adelaide, Adelaide, South Australia, Australia.
7: Boston University Medical Center, Boston, Massachusetts, USA.
8: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Sweden.

Associated clinical trials:

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) | NCT00412984

Articles citing this ↘

Inflammatory biomarkers in atrial fibrillation: are they linked to future outcomes? Heart (2016) 0.75

The Predictive Role of Inflammatory Biomarkers in Atrial Fibrillation as Seen through Neutrophil-Lymphocyte Ratio Mirror. J Biomark (2016) 0.75

Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat Rev Cardiol (2016) 0.75

Articles by these authors ⇆

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82

Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation (2014) 1.65

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart (2014) 1.53

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.43

High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation (2013) 0.99

Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J (2014) 0.93

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol (2013) 0.92

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J (2016) 0.77

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart (2016) 0.76

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J (2016) 0.76

Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". Circulation (2014) 0.75

Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. ACP J Club (2005) 0.75

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc (2017) 0.75

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2016) 0.75

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke (2017) 0.75

Comparison of Bleeding Risk Scores in Patients with Atrial Fibrillation:Insights from the RE-LY Trial. J Intern Med (2017) 0.75

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Am Heart J (2017) 0.75